Your browser doesn't support javascript.
loading
The use of mechanical circulatory support in elective high-risk percutaneous coronary interventions: a literature-based review.
Geppert, Alexander; Mashayekhi, Kambis; Huber, Kurt.
Afiliación
  • Geppert A; 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Clinic Ottakring, Montleartstrasse 37, A-1160 Vienna, Austria.
  • Mashayekhi K; Division of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen, Südring 15, D-79189 Bad Krozingen, Faculty of Medicine of the University, Freiburg, Germany.
  • Huber K; Clinic of Internal Medicine and Cardiology, Heart Center Lahr, Hohbergweg 2, D-77933 Lahr/Schwarzwald, Germany.
Eur Heart J Open ; 4(2): oeae007, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38511148
ABSTRACT
Contemporary medical practices allow complete percutaneous coronary intervention (PCI) in a considerable number of patients who previously would have been considered too 'high-risk' for such procedures. The use of mechanical circulatory support (MCS) devices during these high-risk PCIs (HR-PCIs) is thought to reduce the potential risk for major adverse events during and after revascularization. The intra-aortic balloon pump (IABP), veno-arterial extracorporeal membrane oxygenation (V-A ECMO), and the Impella are the most common MCS devices in use. This review aims to summarize the clinical evidence for each of these devices and the potential mechanisms for the improvement in patient outcomes in HR-PCI. The IABP use has rapidly declined in recent years due to no evidence of benefit in HR-PCI and cardiogenic shock. The V-A ECMO results in low rates of major adverse cardiac and cerebrovascular events (MACCEs) but higher rates of acute kidney injury and increased need for transfusions. In initial studies, Impella resulted in a reduced need for repeat interventions and reduced rates of hypotension, but no benefit in mortality. However, MACCE rates with Impella have gradually declined over the last 10 years, reflecting increased operator experience and technical improvements. Thus, a large, randomized trial is needed to assess the efficacy of Impella in HR-PCI with contemporary standards of care. There is currently no individual parameter that can identify patients who would benefit from MCS use in elective HR-PCI. To address this gap, we propose an algorithm that combines anatomical complexity, comorbidities, and clinical presentation to accurately identify candidates for MCS-assisted HR-PCI.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur Heart J Open Año: 2024 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur Heart J Open Año: 2024 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Reino Unido